One of the usual bashers has another identity over

One of the usual bashers has another identity over at SA. I've been wrestling him to the ground when he bashes over there (he's been virulent). He claims to be an amateur investor, yet has posted nearly 4,000 comments. Uh-huh. Here's the latest bash -- he has been mega-bearish, now has egg on face after yesterday's PR, so uses this as yet another chance to bash CTIX:

Quote:

---

GrowthGeek
Comments (3865) |
More solid news in regards to Brilacidin today in the OM Phase 2 trial. Now CTIX needs to figure out how to fund Phase 3 Brilacidin trials. Brilacidin is their best bet for FDA approval and profit. Management needs to get it's head out of the sand and get moving. Prurisol licensing deal? I hope so.


Drrano
Comments (129) |+ Follow
This management has managed to get 3 different drugs into clinical trials for 5 utterly different conditions. They have done this with very little funding, and have fought back against attacks by an avowed short seller and a frivolous lawsuit that a Federal judge has found to be without merit.
This is hardly a management that did not "get moving" and certainly not one that has its head in the sand. News of a drug that certainly appears to be safe and effective for a debilitating side effect of radiation is greeted with insulting the management which has very quickly gotten the drug to this point? Do you really think a management that has been so successful thus far has no idea of how to continue? The CEO has often stated that he is pursuing partnerships, that major pharmaceutical companies have signed confidentiality agreements, and that study protocols were redesigned in a way that a potential partner requested. Your criticism of this management is unfair and unwarranted.

---